Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

RNXTBullishCorporate Developmentsnews

High materiality7/10

RenovoRx regains Nasdaq compliance; momentum builds toward TIGeR-PaC readout

Aug 21, 2026, 8:37 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Removing delisting risk and signaling ongoing commercial/clinical progress lowers overhang and may support a multiple re-rating; however, lack of immediate profitability keeps upside modest until 2027 data readout.

AI summary

What happened, with direct paths to the underlying reporting

RenovoRx has regained Nasdaq Capital Market compliance after a deficiency dating back to December 2025, with the stock closing at or above $1 for 10 consecutive trading days (Aug 6-19, 2026). The company also highlighted record Q2 revenue, expansion of RenovoCath usage, a first commercial sarcoma case, and full enrollment in the TIGeR-PaC Phase III trial, with topline data expected in 2H2027. These factors collectively reduce listing risk and add near- to mid-term catalysts for RNXT investors.

RenovoRx regained Nasdaq minimum bid price compliance.
Nasdaq: closing bid price >= $1 for 10 consecutive days (Aug 6-19, 2026).
Q2 2026 revenue: $0.909 million; 2025 RenovoCath revenue: $1.1 million.
First commercial RenovoCath use in sarcoma reported; active center expansion.
TIGeR-PaC Phase III enrollment complete; topline data in 2H2027; trial completes 1H2027.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.